- Home
- CAPR vs CLMB Comparison
CAPR vs CLMB Comparison
Compare CAPR & CLMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- CLMB
- Stock Information
- Founded
- CAPR 2005
- CLMB 1982
- Country
- CAPR United States
- CLMB United States
- Employees
- CAPR N/A
- CLMB N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- CLMB Retail: Computer Software & Peripheral Equipment
- Sector
- CAPR Health Care
- CLMB Technology
- Exchange
- CAPR Nasdaq
- CLMB Nasdaq
- Market Cap
- CAPR 525.3M
- CLMB 542.4M
- IPO Year
- CAPR N/A
- CLMB N/A
- Fundamental
- Price
- CAPR $9.48
- CLMB $110.58
- Analyst Decision
- CAPR Strong Buy
- CLMB Buy
- Analyst Count
- CAPR 7
- CLMB 1
- Target Price
- CAPR $39.29
- CLMB $136.00
- AVG Volume (30 Days)
- CAPR 1.5M
- CLMB 42.4K
- Earning Date
- CAPR 03-19-2025
- CLMB 03-05-2025
- Dividend Yield
- CAPR N/A
- CLMB 0.61%
- EPS Growth
- CAPR N/A
- CLMB 49.27
- EPS
- CAPR N/A
- CLMB 4.06
- Revenue
- CAPR $22,270,465.00
- CLMB $465,607,000.00
- Revenue This Year
- CAPR $34.33
- CLMB $7.01
- Revenue Next Year
- CAPR $246.72
- CLMB N/A
- P/E Ratio
- CAPR N/A
- CLMB $27.24
- Revenue Growth
- CAPR N/A
- CLMB 32.27
- 52 Week Low
- CAPR $3.52
- CLMB $49.70
- 52 Week High
- CAPR $23.40
- CLMB $145.00
- Technical
- Relative Strength Index (RSI)
- CAPR 33.11
- CLMB 39.46
- Support Level
- CAPR $12.64
- CLMB $106.82
- Resistance Level
- CAPR $13.81
- CLMB $112.49
- Average True Range (ATR)
- CAPR 1.18
- CLMB 4.65
- MACD
- CAPR -0.32
- CLMB -0.37
- Stochastic Oscillator
- CAPR 9.83
- CLMB 24.53
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About CLMB Climb Global Solutions Inc.
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The Company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.